Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?
On Dec. 14, Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) jointly reported some great news for patients as well as investors: A powerful new cancer therapy is in the works, and the freshly published mid-stage clinical trial data look favorable. Now, the biotech's shares are up by 21% over the last 30 days, and they likely have much further to run over the long term.
But the coronavirus vaccine developer's stock actually lost a similar proportion of its value over the last three years, and its revenue is dramatically lower than during its heyday. Is Moderna's stock still a buy, or is the collaboration with Merck much ado about more of the same?
Moderna is intent on proving that its vaccines can be helpful in treating serious diseases rather than merely helping to prevent them.
Source Fool.com
Moderna Inc. Stock
We see a rather positive sentiment for Moderna Inc. with 16 Buy predictions and 2 Sell predictions.
With a target price of 125 € there is a slightly positive potential of 7.63% for Moderna Inc. compared to the current price of 116.14 €.
